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Sir,
We note the recent paper of Hamana et al (2005) in your journal
with interest and have some observations in the light of a similar
pilot study that we presented last year at the 2004 International
Conference on Head & Neck Cancer (Thomas et al, 2004).
Our study aimed to establish whether genetic alterations
observed in preoperative circulating DNA were maintained after
surgical treatment and if this could be related to outcome.
Similarly to the Hamana study, DNA was isolated from tumour
tissue, white blood cells as control DNA, pre- and postoperative
plasma from each of six oral cancer patients and microsatellite
analysis was used to measure allelic imbalance (AI). However, in
our study 22 markers were used instead of nine, with the result that
AI was detected in 100% of tumours (six of six) rather than the
59% (38 of 64) observed in the Hamana study. Our markers were
also chosen to include those that have previously demonstrated AI
in oral SCC and we were surprised to note that Hamana et al did
not include any markers from 3p21, 3p14 or 17p13.1. The other
main difference in our study was that our clinical follow-up and
investigation of plasma specimens continued for a minimum of 2
years.
In four of six (67%) of our patients, presurgery circulating DNA
showed allelic imbalance at 41 locus that demonstrated AI in
tumour DNA. This is similar to the data obtained by Hamana et al,
who observed AI in preoperative plasma in 28 of their 38 (74%)
patients with AI-positive tumours. Although we have no data
immediately postsurgery, it was interesting to note that the
incidence of AI in circulating DNA in the Hamana study
DECREASED (13 of 38; 34%) at this time point, when it would
be expected to remain high due to tumour-specific DNA persisting
in the circulation before degradation and clearance. However, the
authors do not indicate the exact time of sampling for their
postsurgery plasma and these data may be a result of reduced
sensitivity of the AI technique when nontumour DNA is released
into the bloodstream during the trauma of surgery. Our post-
operative follow-up plasma samples were obtained at 24–48
months and AI was retained at five of the nine and one of the eight
markers in samples from two patients who developed locoregional
recurrence. None of our patients developed distant metastases. Our
data show the potential for this technique in the early detection of
locoregional recurrence and augments the data of Hamana et al,
which shows value in predicting distant metastases. Indeed their
data suggest that persistence of DNA aberrations at 4 weeks after
surgery had a 100% positive predictive value for distant
metastases. Four weeks is often the point used to prescribe
postoperative radiotherapy or combined chemo-radiotherapy
(POCRT). In the context of recent trials advocating POCRT
in poor prognosis head and neck cancer (Cooper et al, 2004;
Bernier et al, 2005), this finding offers promise in clinical
translation.
The potential for use of circulating DNA in head and neck
cancer has been demonstrated by this and other studies (Nawroz-
Danish et al, 2004); however, the question arises as to the best
method of analysing genetic or epigenetic aberrations. Most
patients are noninformative for at least one marker and these AI
techniques become insensitive in the face of ‘contamination’ with
normal DNA such as after trauma, surgery or blood transfusion.
We speculate that other more sensitive techniques may be more
suited to this rapidly developing field, and clearly, further high-
quality studies such as that of Hamana et al are required.
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